UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2020

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39318	46-3973463
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1920 McKinney Avenue, 7th Floor Dallas, Texas	75201
(Address of Principal Executive Offices)	(Zip Code)

(972) 277-1136
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Common Stock

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.0001 par value	LTRN	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2020, Lantern Pharma Inc. (the "Company") will issue a press release announcing its financial results for the second quarter ended June 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On July 30, 2020, the Company will utilize a presentation to assist with the Company's discussions during a conference call and live webcast hosted by the Company to discuss financial and operating results for the second quarter ended June 30, 2020 A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.2 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Exhibit Description
99.1	Press Release dated July 30, 2020 announcing financial results for quarter ended June 30, 2020.
99.2	Presentation relating to July 30, 2020 conference call and live webcast to discussfinancial and operating results for quarter ended June 30, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lantern Pharma Inc.,
A Delaware Corporation

Dated: July 30, 2020

By: */s/ David R. Margrave*
David R. Margrave, Chief Financial Officer

Exhibit 99.1

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress

Closed Initial Public Offering Raising Gross Proceeds of $26.3 Million

Surpassed 500 Million Curated Oncology Data Points for Company's RADR® A.I. Platform

Advanced Manufacturing Capabilities for LP-300 and LP-184 Trials

DALLAS, TX – JULY 30, 2020 – Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today announced its financial results for the second quarter ended June 30, 2020, and provided an update on its R&D pipeline and other corporate developments.

"Lantern Pharma achieved important scientific and operational milestones during the quarter that have us well positioned for growth as we focus on being the leader in A.I.-enabled oncology drug development," said Panna Sharma, CEO and President of Lantern Pharma. "Our proprietary RADR® platform recently surpassed 500 million data points, further accelerating our path to one billion curated oncology data points in the next few quarters. We have also advanced our manufacturing capabilities and network for our upcoming clinical trials for LP-300 in non-small cell lung cancer among never smokers, and for LP-184 in genomically defined solid tumors and glioblastoma. On June 15, we completed a successful IPO, raising gross proceeds of $26.3 million, significantly strengthening the Company's balance sheet and provides additional resources to support the continued development of our promising and growing pipeline of targeted cancer therapies. Our approach and vision is to bring cancer therapies to market faster and with reduced cost and risk and ultimately improve patient outcomes. We are entering what I believe is the Golden Age of A.I. where industries will continue to be rapidly transformed and massive advancements made that can benefit medicine, health and those willing to invest in and develop these disruptive opportunities."

Corporate and Scientific Highlights

- **Closed initial public offering** – In June 2020, Lantern Pharma closed its initial public offering of 1,750,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of $26,250,000, before deducting underwriting discounts, commissions and offering expenses.

- **Initiated multiple preclinical studies for LP-184 in genomically defined solid tumors and Glioblastoma (GBM) -** The studies aim to further validate the genomic signature of LP-184 and help to inform IND development efforts. The data generated in these studies will also support the continued expansion of our RADR® (Response Algorithm for Drug Positioning and Rescue) A.I. platform.

- **RADR® surpasses 500 million data points** – Lantern Pharma is ahead of its initial platform development schedule of reaching 400 million data points by the end of 2020. The Company is now on track to reach over 1 billion data points within the next several quarters.

- **Presented at American Association for Cancer Research (AACR)** – Two presentations that detailed Lantern Pharma's use of its RADR® A.I. platform in the development of LP-184, a molecule with nanomolar potency and strong activity in cancers with KEAP1 and KRAS mutations. LP-184 is one of three cancer drug candidates in Lantern Pharma's pipeline.

- **Advanced manufacturing capabilities and network to support LP-300 and LP-184 trials** – the Company established a manufacturing network in preparation for its Phase 2 clinical trial of LP-300 in non-small cell lung cancer among never smokers and for LP-184 in preclinical development for genomically defined solid tumors that overexpress certain RNA as well as for glioblastoma multiforme.

- **Continue to advance our collaborations with leading academic and cancer research centers** - for the purposes of examining additional potential cancer indications for our drugs, improving and validating the existing genomic signatures that correspond to patient response, establishing sites, and recruiting potential investigators for upcoming clinical trials.

Q2 2020 Financial Highlights

Cash Position: Cash and cash equivalents were $23.8 million as of June 30, 2020, compared to $1.2 million as of December 31, 2019. The increase was primarily due to proceeds from the IPO in June 2020.

R&D Expenses: Research and development expenses were $157,023 for the quarter ended June 30, 2020, compared to $361,273 for the quarter ended June 30, 2019. The decrease was primarily attributable to reductions in product candidate manufacturing related expenses reflecting completion of process development and scale-up studies conducted in the prior year period.

G&A Expenses: General and administrative expenses were $676,399 for the quarter ended June 30, 2020, compared to $268,120 for the quarter ended June 30, 2019. This increase was primarily due to an increase in expenses associated with transitioning to and becoming a public company.

Net Loss: Net loss was $833,422 for the quarter ended June 30, 2020, compared to a net loss of $629,393 for the quarter ended June 30, 2019.

Sharma continued, “Developing drugs by leveraging artificial intelligence is central to transforming the cost and efficiency of the pharma industry and improving the personalization of therapies for cancer patients. By identifying clinical candidates, together with relevant genomic, clinical and phenotypic data, we believe our approach will help us design more efficient pre-clinical studies and more targeted clinical trials, thereby accelerating our drug candidates’ time to approval and eventually to market. RADR® is central to our process in achieving this outcome rapidly and with reduced costs. We currently have three compounds in development, one in a Phase 2 trial in prostate cancer with our partner, Oncology Venture, one that is preparing to enter into a Phase 2 trial, and one in preclinical development,”

“We believe we have developed a sustainable and scalable biopharma business model by combining a unique, oncology-focused big-data platform that leverages artificial intelligence and machine learning with active clinical and preclinical programs that are being advanced in targeted cancer therapeutic areas with significant clinical needs,” concluded Sharma.

Conference Call:

Lantern Pharma will host a conference call and webcast today at 8:00 a.m. ET.

Conference Call & Webcast Details

- Toll-free Domestic & Canada: 800.791.4813 – conference ID 10552
- International: 785-424-1102 – conference ID 10552
- US and Canada callers one touch dial: +1.800.791.4813,,10552#

The webcast will be available in the “Investors” section of the company website at https://ir.lanternpharma.com/ under the News & Events page.

Replay Details

A replay of the conference call will be available for replay until 11:59 pm ET August 30, 2020.

Replay Number: 1-888-567-0053, no passcode will be needed.

A live audio-only webcast and related presentation materials will also be accessible on the Lantern Pharma corporate website: https://ir.lanternpharma.com/. Web participants are encouraged to register 15 minutes prior to the start of the call. The webcast will be archived on the Lantern Pharma website for 6 months.

About Lantern Pharma

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I. platform to discover biomarker signatures that help identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern's focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Our current pipeline of three drugs, with two programs in clinical stages and two in preclinical, focuses on cancers that have unique and unmet clinical needs with a clearly defined patient population. We believe that the use of machine learning, genomics and computational methods can help accelerate the revitalization, refocusing and development of small molecule-based therapies. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, this approach represents the potential to deliver best-in-class outcomes. Our team seeks out experienced industry partners, world-class scientific advisors, and innovative clinical-regulatory approaches to assist in delivering cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.lanternpharma.com or Twitter @lanternpharma.

Contact:
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
investor@lanternpharma.com

Forward-looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates; estimates regarding the development timing for our drug candidates; our strategic plans to expand the number of data points that our RADR® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management "believes", "expects", "anticipates", "estimates", "plans" (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as the impact of the COVID-19 pandemic, the results of our clinical trials, and the impact of competition. Additional factors can be found in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Condensed Consolidated Balance Sheets

	June 30, 2020 (unaudited)	December 31, 2019
CURRENT ASSETS		
Cash	$ 23,798,343	$ 1,232,030
Other current asset	1,728,539	-
Prepaid expense	70,775	788
Total current assets	25,597,657	1,232,818
Property and equipment, net	15,377	8,758
Deferred offering costs	-	191,000
TOTAL ASSETS	$ 25,613,034	$ 1,432,576
CURRENT LIABILITIES		
Accounts payable and accrued expenses	$ 467,988	$ 489,292
Insurance payable	1,705,846	-
Note payable	102,831	-
Total current liabilities	2,276,665	489,292
Loan payable	108,500	-
TOTAL LIABILITIES	2,385,165	489,292
STOCKHOLDERS' EQUITY		
Preferred Stock - Par Value (1,000,000 authorized at June 30, 2020; 3,480,000 authorized at December 31, 2019; $.0001 par value)		
(Zero shares issued and outstanding at June 30, 2020; 2,438,866 shares issued and outstanding at December 31, 2019)	-	244
Common Stock – Par Value (25,000,000 authorized at June 30, 2020; 12,180,000 authorized at December 31, 2019; $.0001 par value)		
(6,217,577 shares issued and outstanding at June 30, 2020; 1,978,269 shares issued and outstanding at December 31, 2019)	622	198
Additional paid-in capital	31,289,650	7,694,547
Accumulated deficit	(8,062,403)	(6,751,705)
Total stockholders' equity	23,227,869	943,284
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 25,613,034	$ 1,432,576

Condensed Consolidated Statements of Operations (Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2020	**2019**	**2020**	**2019**
Operating expenses				
General and administrative	676,399	268,120	1,016,571	536,049
Research and development	157,023	361,273	294,127	547,317
Total operating expenses	833,422	629,393	1,310,698	1,083,366
NET LOSS	$ (833,422)	$ (629,393)	$ (1,310,698)	$ (1,083,366)
Net loss per share of common shares, basic and diluted	$ (0.31)	$ (0.32)	$ (0.55)	$ (0.55)
Weighted-average number of common shares outstanding, basic and diluted	2,719,198	1,978,269	2,370,082	1,978,269

Exhibit 99.2

Lantern Pharma®

Second Quarter 2020

Operating & Financial Results Conference Call



https://ir.lanternpharma.com/

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates; estimates regarding the development timing for our drug candidates; our strategic plans to expand the number of data points that our RADR® platform can access and analyze; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements to the effect that Lantern Pharma Inc. or our management "believes", "expects", "anticipates", "estimates", "plans", and words such as “targets,” “objectives” (and similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements such as the impact of the COVID-19 pandemic, the results of our clinical trials, and the impact of competition. Additional factors can be found in the Risk Factors section in our final prospectus, dated June 10, 2020, for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this presentation represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Lantern Pharma

Second Quarter 2020

Operating and Financial Results
Conference Call

1. Business Overview & Background
   Panna Sharma, CEO
2. Financial Results & IPO Summary
   David Margrave, CFO
3. Future Outlook & Milestones
   Panna Sharma, CEO
4. Q&A Session

Entering "The Golden Age of A.I."

10 Mega-Trends Setting The Stage for A.I. Led Transformation in Drug Development & Medicine

- Large-scale, relevant and readily available data-sets
- Methods, technologies and algorithms that are massively scalable
- Computing, storage and transmission continue exponential advances
- Rapid rise of global talent and collaboration networks
- Tremendous increase in quality of biological data and methods
- Rise of sequencing as a highly available, on-demand, low-cost service
- Consumers willing to share personal data in near-time
- Industries that have an increasing impetus to transform
- New generation of investors demanding novel value creation
- Executives and entrepreneurs rewarded for rapid change

Lantern is at the forefront of this model of A.I. driven transformation in the area of personalized oncology drug development to drive value for cancer patients and our investors.



Precision Medicine Platform

RADR® rapidly identifies genetic & biomarker signatures for precision oncology drug development, clinical response prediction and CDx (companion diagnostic) enablement.

We continue to invest in the platform's functionality, scale, and volume of data.

RADR® Platform Key Features & Architecture



RADR® Platform Continues to Grow in Volume and Functionality

Precision Medicine Platform

Lantern's powerful A.I. platform is being developed with a pure focus on predicting drug outcome and drug response using a depth of interrelated biomarker and clinical data, including:

- Complete transcriptome data
- RNA gene expression data
- Drug sensitivity data
- DNA copy number and mutation data
- Clinical stage of tumor/cancer
- Histology of tumor
- Patient age and sex
- Patient race or ethnicity
- Prior treatment history and response

Data Powering **RADR®**



10 Million >	**125 Million >**	**400 Million >**	**1 Billion >**	**3-5 Billion >**
2018	2019	2020	2021	2022

Precision Medicine Platform

RADR® automates machine-learning approaches in generating a biomarker based response signature that can be used throughout the lifecycle of therapy development:

1. Preclinical modeling and studies
2. Clarifying mechanisms of action
3. Launching a robust companion diagnostic (CDx).
4. Identifying additional potential combination drugs or therapies

Biomarker Signature is Based on Statistical Significance and Biological Relevance



Output & Signature Development Process

Precision Medicine Platform



10 Million > 2018 | 125 Million > 2019 | 400 Million > 2020 | 1 Billion > 2021 | 3-5 Billion > 2022

Curated Data Sources Include:

- *Historical Trials*
- *Proprietary Internal Studies*
- *Studies & Collaborations w/ Partners*
- *Active Clinical Trials*
- *Trials in adjacent drug classes and tumors*
- *Proprietary Sequencing Campaigns*
- *Proprietary Drug Sensitivity Studies*
- *Open Sources from Publications and Research*
- *Clinical Outcome & Lab Data From Select Groups*

The RADR® Platform Enables...

Scientific Value +

1. Rapid identification of potential compounds to rescue and develop
2. Improved and more nuanced understanding of responder groups, and non-responder groups based on biological networks
3. Feedback for potential mechanisms to be exploited in target-based development activity

Patient Value +

4. More rapid entry into clinical trials and patient subgroups
5. Robust companion diagnostics that can be used to accelerate trials and commercial traction
6. Potential for improved patient outcomes with drastically reduced costs and economic burden

Lantern's Unique & Rapidly Developing Pipeline



Accelerated Development by Leveraging the RADR® A.I. platform

108 issued patents and 7 pending applications across 14 patent families

Summary Results of Operations*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2020	**2019**	**2020**	**2019**
Operating expenses:				
General and administrative	676,399	268,120	1,016,571	536,049
Research and development	157,023	361,273	294,127	547,317
Total operating expenses	833,422	629,393	1,310,698	1,083,366
NET LOSS	**$ (833,422)**	**$ (629,393)**	**$ (1,310,698)**	**$ (1,083,366)**
Net loss per common share, basic and diluted	$ (0.31)	$ (0.32)	$ (0.55)	$ (0.55)

* Unaudited

Lantern Pharma

Summary of Initial Public Offering

Date Closed:	June 15, 2020
Shares Sold:	1,750,000 shares
Price:	$15.00 per share

LANTERN PHARMA INC. (Nasdaq : LTRN)	
Common Shares Outstanding	6,217,577
Warrants (Weighted Average Exercise Price of $3.13)	262,014
Underwriter Warrants (Exercise Price at $18.75)	70,000
Options (Employees, Management and Directors)	820,608
Fully Diluted Shares Outstanding	**7,370,199**

Gross Proceeds
$26,250,000 USD

Net Proceeds
$23,420,000 USD

Nasdaq
Ignite your ambition

Balance Sheet Highlights & Summary

	06/30/2020 *(Unaudited)*	12/31/2019
Cash	**$ 23,798,343**	**$1,232,030**
Other Current Asset	$1,728,539	-
Prepaid Expense	$70,775	$788
Total Assets	**$ 25,613,034**	**$ 1,432,576**
Total Liabilities	**$ 2,385,165**	**$ 489,292**
Total Stockholders' Equity	**$ 23,227,869**	**$ 943,284**

Key Value Building Objectives

Foundational Year
Advance Platform
Prepare Trial Launches
Prioritize Additional Compounds

Second Half of 2020

- Advances for launch of LP-184 IND-Enabling studies
- Data from collaboration with Georgetown in Prostate and Pancreatic Cancers
- Results from preclinical work in Glioblastoma w/ LP-184
- FDA related activity to explore launch of Phase 2 for LP-300 as a rare cancer trial for never-smoking females
- Further validation of RADR® platform and signatures
- Validate signature for LP-184 to design pan-tumor clinical studies and trial
- Focus on increasing RADR® A.I. Platform to 700+ million data points

Multiple Streams of Value Creation
Launch Multiple Precision Trials
Leverage Platform for Pharma Partners
Secure Additional Compounds

2021-22

- Readout from targeted Ph. 2 trial in Europe in prostate cancer by first half of 2021 with LP-100
- Launch Ph. 2 clinical trial for LP-300 in NSCLC (never-smokers) by mid 2021
- Launch Ph. 1 clinical trial for LP-184 in solid tumors
- Launch Ph. 1/2 clinical trial for LP-184 in GBM
- Explore potential combinations for LP-184 & LP-300 with other existing approved drugs (inc. I-O agents)
- Strategically grow RADR® A.I. Platform beyond 1 Billion data-points
- Big pharma partnership and collaboration on drug rescue, repurposing or development

Upcoming Conference & Presentation Schedule

7/31/20	LD Micro -- "Zooming with L.D."
8/24 - 8/27/20	World Orphan Drug Congress USA
9/8 - 9/10/20	MedInvest A.I., Big Data & Digital Health Conference
9/10/20	Colliers 5th Annual Institutional Investor Conference
9/14 - 9/16/20	H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Unless otherwise noted, all events are virtual and based on confirmed registration and subject to the policies of the event organizer.

Lantern Pharma

Investor Contact:
Marek Ciszewski, J.D.
investor@lanternpharma.com
ph: 1.628.777.3167

Q & A

LTRN Operating & Financial Results Call
July 30, 2020